By: Benzinga
UPDATE: Canaccord Genuity Reiterates Buy Rating, Raises PT on Aegerion Pharmaceuticals
In a report published Wednesday, Canaccord Genuity reiterated its Buy rating on Aegerion Pharmaceuticals (NASDAQ: AEGR ), and raised its price target from $27.00 to $36.00. Canaccord Genuity noted, “AEGR announced additional Juxtapid launch color, with the key takeaways being the $235K/$295K U.S. annual pricing (vs. our $250K estimate) for
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here